IPF

AstraZeneca will use BenevolentAI’s advanced AI to dive into its disease area expertise and massive datasets to gain insights into the complex disease biology

AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney…

5 years ago

Boehringer Ingelheim: Global survey reveals the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF)

61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1  Survey underlines the importance of…

7 years ago